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Pharmacologic manipulation of glomerular function
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Normally, the glomerular filtration rate (GFR) is kept nearly
constant. This is achieved by the autoregulation of the renal
blood flow and by the tubuloglomerular feedback mechanism
[1, 21. Renal blood flow is in part autoregulated by changes in
afferent arteriolar resistance. Thus, increases in systemic blood
pressure will result in a constriction of the afferent arteriole
whereas reductions in systemic blood pressure will induce a
dilation of the afferent arteriole, rendering glomerular blood
flow nearly constant. Nitric oxide and prostaglandins play an
important role in this pressure-induced autoregulation [3]. Like-
wise, the tubuloglomerular feedback mechanism affects afferent
arteriolar, but also efferent arteriolar resistance: a fall in GFR
will lead to a diminished flow in the distal tubule and a
decreased sodium and chloride content at the macula densa. As
a result afferent arteriolar vasodilation and efferent arteriolar
vasoconstriction will occur in order to restore glomerular
filtration. On the other hand, if sodium delivery at the macula
densa enhances, afferent vasoconstriction will ensue. Thus, the
autoregulation of the renal blood flow and the tubuloglomerular
feedback mechanism aim to keep GFR constant.
Glomerular ultrafiltration is determined by four factors [2,
4—6]: (1) the glomerular plasma flow (QA); (2) the transcapillary
hydrostatic pressure difference (zP), which is the difference
between the hydrostatic pressure in the glomerular capillary
and the hydrostatic pressure in Bowman's space, that is, in the
proximal tubule; (3) the oncotic pressure in the glomerular
capillary (TGC), which is the opposite force of P; (4) the
ultrafiltration coefficient of the glomerular basement membrane
(Kf), being the product of the surface area for filtration and the
effective hydraulic permeability of the capillary wall. Whereas
throughout the capillary loops P remains relatively constant,
GC rises progressively as a result of filtration of protein-free
fluid. Experimental studies in rats and primates have revealed
that 1TGC counterbalances zIP before the end of the glomerular
capillary, by which so-called filtration equilibrium ensues. It
has not been elucidated whether in humans a filtration equilib-
rium normally exists also.
Micropuncture studies in rats have demonstrated that QA is
the most important determinant of the glomerular ultrafiltration
both in states of filtration equilibrium and filtration disequilib-
rium [4, 7]. In case of filtration equilibrium, a rise in QA is
followed by a proportional rise in glomerular ultrafiltration until
filtration disequilibrium is reached. In case of filtration disequi-
librium, a rise in QA will be followed by a proportionally lesser
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rise in glomerular ultrafiltration. As a result the filtration
fraction (FF), defined as the glomerular filtration rate divided by
the glomerular blood (plasma) flow, will fall. In case of filtration
equilibrium increments in zIP will not affect GFR. On the other
hand, an elevation in zIP will induce a rise in glomerular
ultrafiltration in cases of filtration disequilibrium, which will be
associated with a rise in FF.
Whenever pharmacological agents affect GFR, they will do
so by affecting one or more of the above-mentioned determi-
nants of the glomerular ultraffitration. In humans the renal
effects of pharmacologic agents are usually evaluated indirectly
by utilizing clearance techniques to determine GFR, effective
renal plasma flow (ERPF) and FF. Subsequently, observed
changes in renal hemodynamics and FF are frequently used to
deduce alterations in the tone of the renal resistance vessels and
the determinants of glomerular ultrafiltration. By means of
mathematical modelling, Carmines et al [8] pointed out that
proportionally similar reductions in afferent and efferent arte-
riolar resistances will result in a fall in FF. Thus, changes in FF
alone cannot be used to deduce alterations in the tone of the
afferent and efferent arterioles, or in the determinants of gb-
merular ultrafiltration. This is especially so when the assump-
tion holds true that filtration equilibrium does not exist in
humans, since filtration disequilibrium implies that a rise in
ERPF always will result in a proportionally lesser increase in
GFR, and thus in a fall of the FF. However, if a pharmacolog-
ical intervention results in opposite effects on GFR and ERPF,
it must be assumed that changes in zIP and Kf have occurred.
Since such changes in zIP and Kf may have additional or
opposing effects on GFR and FF, the interpretation of observed
modifications in FF and renal hemodynamics may not suffice to
extrapolate changes in the determinants of glomerular ultrafil-
tration with certitude. Additional information may be obtained
by simultaneous investigation of the urinary protein loss and/or
dextran clearances.
Non-steroidal anti-inflammatory drugs (NSALD's)
By blocking cycbooxygenase, NSAID's prevent the produc-
tion of the vasodilating prostaglandins [9]. Since the effects of
many vasoconstrictors are modulated by a release of these
vasodilating prostaglandins, the administration of NSAID's
may result in unopposed vasoconstriction. In healthy, sodium
replete individuals, the administration of NSAID's hardly af-
fects ERPF or GFR [10—12]. On the other hand, when healthy
individuals adhere to a sodium-restricted diet NSAID's will
induce a fall in GFR [10]. Sodium restriction induces an
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activation of the renin-angiotensin system. Consequently, an-
giotensin II production is enhanced, resulting not only in
vasoconstriction but also in an augmented synthesis of the
vasodilating prostaglandins. In this setting the administration of
NSAID's will inhibit the production of these vasodilatating
hormones. This will ensue in an amplified constriction of the
afferent and efferent arterioles, and the mesangial cells, result-
ing in a fall in QA, P and Kf. Likewise, in case of volume
depletion or reduction in the effective circulating volume as,
such as, in cardiac failure or cirrhosis of the liver, the secretion
of angiotensin II and norepinephrine is increased. In these
conditions sufficient renal perfusion is critically dependent on
the production of vasodilating prostaglandins. Consequently,
the administration of NSAID's to patients with these conditions
will impair GFR. For reasons not completely understood the
NSAID, sulindac, induces markedly less inhibition of the renal
vasodilating prostaglandins and, therefore, is less likely to
impair renal function in these conditions [9].
The above-mentioned vasoconstrictive effects of NSAID's
constitute the basis for a symptomatic treatment of patients
with nephrotic range proteinuria [10]. In sodium-restricted
nephrotic patients, the administration of NSAID's induces a
decrease in proteinuria which is proportionally larger than the
fall in GFR [10, 11, 13, 14]. This is explained by an augmented
tubular capability to reabsorb filtered proteins as the result of
the decreased GFR and, thus, tubular flow [13, 14]. Moreover,
NSAID's appear to restore the barrier size-selectivity of the
glomerular basement membrane [10, 13, 14], which will con-
tribute to a decrease in proteinuria. Locally produced pros-
taglandins also mediate renin release. Consequently, NSAID's
will impair renin synthesis and can induce hyporeninemic
hypoaldosteronism, which accounts for the occasionally ob-
served hyperkalemia associated with NSAID therapy.
ACE inhibitors
Angiotensin I is converted by the angiotensin converting
enzyme in the potent vasoconstrictor angiotensin II. In the
kidney, angiotensin II induces vasoconstriction of afferent, but
predominantly efferent arterioles [15—17]. The latter may be
contributed to the fact that angiotensin II stimulates the syn-
thesis of vasodilating prostaglandins only in the afferent arte-
riole, and prostaglandins modulate the vasoconstrictor effect of
angiotensin II [18]. As a result of the disproportional constric-
tion of the efferent arteriole, ERPF falls during angiotensin II
administration while zP increases. Although angiotensin II also
induces mesangial contraction which results in a decrease in Kf,
the net effect of angiotensin H administration is a less pro-
nounced fall in GFR than in ERPF and, consequently, a rise in
FF. Furthermore, angiotensin II enhances sodium reabsorption
by direct and indirect effects on the proximal tubule, as well as
by inducing the release of aldosteron. Thus, angiotensin II is an
important factor in the autoregulation of renal blood flow and
GFR.
Micropuncture studies in the rat have revealed that treatment
with an ACE inhibitor indeed was accompanied by a predomi-
nant dilation of the efferent arteriole [19, 20]. This resulted in a
rise in QA, a fall in P, and an unchanged GFR. Hollenberg et
al [21] demonstrated that the administration of an ACE inhibitor
acutely lowered blood pressure and improved renal blood flow
in healthy individuals. This effect was more pronounced when
the subjects adhered to a sodium-restricted diet. In patients
with essential hypertension, the ACE inhibitor-induced rise in
renal blood flow exceeded that of the control persons [21, 221.
The observation that creatinine clearance decreased in the
control persons but did not change in patients with essential
hypertension implies ACE inhibition-induced changes in tP
and/or K1. The ACE inhibitor-induced decrease in systemic
blood pressure may at least partially account for the fall in AP.
On the other hand, the observed effects of ACE inhibitors are in
accord with their presumed predominantly vasodilatory effect
on the efferent arteriole, which also causes P to fall. In control
subjects such changes in P and K1 can not be offset by a rise
in renal blood flow, whereas the larger rise in renal blood flow
in patients with essential hypertension apparently can.
A number of studies have reported that in patients with
chronic renal failure ACE inhibition decreased urinary protein
loss, a phenomenon associated by a fall in FF [23—30]. Such a
decrease in proteinuria may be based on a fall in P. Of note,
however, Heeg et al [25] demonstrated that ACE inhibition
induced a prompt reduction in GFR and an increase in ERPF,
and, therefore, a fall in FF, whereas the maximal antiprotein-
uric effect of ACE inhibition was only achieved after 8 to 12
weeks of treatment. This observation indicates that the initial,
ACE inhibitor-induced fall in proteinuna might be the result of
changes in renal hemodynamics but that other factors seem to
be involved in the long-term effects of ACE inhibitors, such as
an improvement in permselectivity of the glomerular basement
membrane [28, 31, 32] and/or prevention of angiotensin II
induced glomerular hypertrophy [17]. The fact that, in the
majority of the studies published to date, prolonged administra-
tion of ACE inhibitors resulted in a reduction in proteinuria but
did not affect GFR and ERPF [33] is in accord with this
assumption.
Interestingly, as shown by Heeg et al [34], combined inhibi-
tion of prostaglandin synthesis and angiotensin II generation
leads to the lowest values for GFR and urinary protein loss in
proteinuric patients. This suggests a pre- and afterload reduc-
tion of glomerular filtration pressure as the basis of this additive
effect of NSAID therapy and ACE inhibition.
In experimental models of renal disease, ACE inhibitor
therapy not only reduces proteinuria but also prevents progres-
sion to end-stage renal insufficiency. Based on the results of
these studies, considerable attention has been focused on the
effects of ACE inhibitors on the progression of chronic renal
failure in humans. As was recently reviewed in detail [33], so far
there are only two randomized studies in which patients with
non-diabetic nephropathy were followed for two or more years
[35, 361. The results of these studies indicate that ACE inhibi-
tors may possess renoprotective effects. To date it is not clear
from the available studies, however, whether these possible
renoprotective effects are due to an improved blood pressure
control per se or whether ACE inhibitors confer specific reno-
protective effects which make them superior to other antihy-
pertensive agents, as has been concluded from several, but not
all [37, 38], experimental studies [19, 39, 40].
Calcium antagonists
To date, three classes of calcium antagonists are available:
phenylalkylamines (that is, verapamil), benzothiazepines (dilt-
iazem), and dihydropyridines (such as nifedipine, isradipine).
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Their common characteristic is that they are able to inactivate
the L-type calcium channel, thus inhibiting calcium entry into
the cell. At high concentrations, however, individual agents
possess non-"class" vasodilatory effects. This holds particu-
larly true for verapamil and diltiazem [41].
Studies in isolated perfused normal and hydronephrotic kid-
neys have revealed that calcium antagonists exert no effects in
the basal, vasodilatated state [42, 43]. Thus, in the isolated
perfused kidney, renal perfusate flow and GFR are not affected
in the basal state. On the other hand, after vasoconstriction is
induced by norepinephrine or angiotensin II, calcium antago-
nists restore GFR despite having only a modest effect on renal
perfusate flow [44, 45]. This suggests that these agents provoke
predominantly afferent vasodilation. Utilizing in vivo and in
vitro hydronephrotic kidneys, it has been visualized indeed that
calcium antagonists induce dilation of preglomerular vessels
without affecting postglomerular ones [46, 47].
Utilizing the remnant kidney model, Anderson reported that
verapamil and diltiazem lowered GFR as a result of a decrease
in zP [48]. This fall in P was attributed to the calcium
antagonist-induced reduction in systemic blood pressure since
afferent and efferent arteriolar resistances had not changed.
Likewise, Yoshioka et al demonstrated in this experimental
model a decrease in GFR and P which, however, emerged as
the result of a verapamil-induced reduction of afferent and
efferent arteriolar resistances [49]. On the other hand, Brunner,
Hermle and Thiel observed a verapamil-induced decrease in
blood pressure, which resulted in a fall in GFR despite a rise in
AP provoked by predominantly afferent vasodilation [50]. Fi-
nally, Dworkin et al demonstrated in the DOCA-salt model that
nifedipine treatment normalized blood pressure without lower-
ing GFR or P [51]. The latter could be explained by the
observed nifedipine-induced dilation of the afferent arteriole.
Thus, the results of micropuncture studies are less consistent.
Nevertheless, it may be summarized from several in vivo and in
vitro observations in diverse experimental models that calcium
antagonists predominantly antagonize preglomerular vasocon-
striction.
Several investigators have reported that calcium antagonists
have no effect on GFR and ERPF of healthy volunteers [52—54].
On the other hand, calcium antagonists have shown to provoke
increments in ERPF and GFR in patients with essential hyper-
tension [53, 55]. Interestingly, it has been demonstrated that
normotensive offspring of hypertensive patients also exhibit a
calcium antagonist-induced rise in GFR and ERPF [56, 57]. The
latter suggests an inherited trait associated with essential hy-
pertension. Whether these increments in ERPF and GFR are
the result of calcium antagonist-induced, predominantly affer-
ent vasodilation has not been clarified yet. Leonetti et al
reported that 'erapamil and nifedipine did not affect GFR
despite a reduced blood pressure [52]. Likewise, Sunderrajan,
Reams and Bauer found that diltiazem induced similar changes
in ERPF and GFR, rendering FF constant [58]. These observa-
tions are in accord with the presumed calcium antagonist-
induced vasodilation of the afferent arteriole. Amodeo et a!,
however, reported a diltiazem-induced fall in FF, suggesting a
proportional decrease in afferent and efferent resistances, or a
predominantly postglomerular vasodilation [59]. In patients
with renal insufficiency variable results have been obtained.
This may be due to structural damage of renal vessels, resulting
in a fixed renal vascular resistance [60].
Dworkin et al recently demonstrated in the remnant kidney
model that nifedipine treatment precluded the progression of
chronic renal failure despite unchanged renal hemodynamics
and a persistently elevated AP. Nifedipine prevented the devel-
opment of glomerular hypertrophy [38, 51, 61]. Subsequently,
these investigators hypothesized that progressive renal damage
might be related to the wall tension of glomerular capillaries,
rather than to P alone [61, 62]. Accordingly to the LaPlace
relationship, glomerular capillary pressure and the radius of
blood vessels equally contribute to the development of wall
tension. Consequently, it can be understood that both a reduc-
tion in P and glomerular hypertrophy reduce wall tension,
which may attenuate progressive renal injury. Apart from their
antihypertensive properties, several other mechanisms have
been postulated by which calcium antagonists may protect renal
function, including modulation of mesangial traffic of macro-
molecules, reduction of renal metabolic activity, amelioration
of uremic nephrocalcinosis, attenuation of mitogenic effects of
growth factors, and decreased free radical formation [63].
These mechanisms may also be involved in several of the
observed beneficial effects of calcium antagonists. As reviewed
elsewhere in more detail [63], in experimental and clinical forms
of acute renal failure, like radiocontrast-induced and post-
transplant acute renal failure, prophylactic treatment with cal-
cium antagonists has resulted in protection against development
of acute renal insufficiency. Likewise, calcium antagonists
possessed renoprotective effects in several experimental mod-
els of renal disease. To date, however, it has not been ascer-
tained whether calcium antagonists manifest renoprotective
properties in human renal disease.
Dopamine
Dopamine, an endogenous catecholamine, interacts with
specific dopaminergic receptors, which are among others lo-
cated in the cardiac, coeliac, mesenteric and renal vascular
beds [64]. At subpharmacological doses (1 to 3 g/kg/niin i.v.)
dopamine causes vasodilation of the mesenteric and renal
blood vessels without affecting heart rate or systemic blood
pressure, and induces natriuresis. At higher doses dopamine
i.v. increases cardiac output due to its beta-adrenergic receptor
activity. At doses exceeding 20 g/kgImin, alpha receptors are
activated and the agent induces a dose dependent vasoconstric-
tion [64].
In healthy individuals administration of low-dose dopamine
(1.5 to 2.0 g/kg/min) induces increments in GFR and ERPF
[65]. Since the rise in ERPF exceeds the rise GFR, FF falls. It
has been demonstrated that dopamine dilates isolated perfused
afferent and efferent arterioles [66]. Furthermore, studies in the
hydronephrotic kidney showed that a dopaminergic agonist
dilated pre-constricted afferent and efferent arterioles to the
same extent [67]. Thus, in accord with the mathematical model
of Carmines et al [8], the dopamine-induced fall in FF may be
explained by proportionally similar decrements in the resis-
tance of afferent and efferent arterioles. Reductions in P
and/or K1, however, may contribute to the dopamine-induced
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fall in FF. The observation that during short-term infusion of
dopamine, proteinuria decreased in uninephrectomized sub-
jects, favors the assumption that dopamine may predominantly
dilate efferent arterioles, resulting in a fall in EP [68].
Since dopamine acutely affects renal hemodynamics, it has
been utilized in patients with renal disease and subjects with a
single kidney to test the presence or absence of glomerular
hyperfiltration. The former is supposed to contribute to pro-
gression of renal insufficiency, provided that such glomerular
hyperfiltration is based on glomerular hypertension, not on
glomerular hyperperfusion [19]. In patients with IgA nephrop-
athy, the dopamine-induced increase in GFR correlated posi-
tively with baseline GFR if baseline GFR exceeded 73 mI/mini
1.73 m2 [691. In a later study this observation was extended to
subjects with other renal diseases: above 50 mIIminil .73 m2 the
dopamine-induced rise in GFR correlated positively with base-
line GFR whereas below this limit dopamine did not affect GFR
[65]. In both studies a close correlation was found between the
dopamine-induced rises in GFR and ERPF, suggesting that the
rise in GFR was mainly obtained by a rise in QA. From these
observations it may be concluded that with declining GFR
glomerular hyperfiltration ensues which, however, seems to be
based on glomerular hyperperfusion.
It is well known that a compensatory rise in GFR ensues in
the remaining kidney after uninephrectomy [70]. Infusion of
dopamine increases GFR and ERPF also in uninephrectomized
subjects [71, 72]. The percent dopamine-induced change in
GFR and ERPF, however, was significantly less than the
percent dopamine-induced change in GFR and ERPF of control
subjects. This was most convincingly demonstrated in living-
related kidney donors before and after kidney donation [73].
Short-term after kidney donation, baseline GFR amounted to
65% of its value before donation. Since the dopamine-induced
increase in ERPF amounted to 69%, FF had fallen significantly.
The dopamine-induced rise in GFR was 13.8% before, and 5.3%
after donation. Thus, it was concluded that the glomerular
hyperfiltration after uninephrectomy was at least partially based
on a compensatory rise in the renal plasma flow. In a subse-
quent study was demonstrated that, compared to short-term
after kidney donation, GFR had improved further in the long
term, whereas ERPF had not changed [68]. Consequently, FF
had risen. This observation may be explained by glomerular
hypertrophy, which is well-known to occur after uninephrec-
tomy. In addition, the percent dopamine-induced changes in
GFR and ERPF of kidney recipients have been reported to be
lower than that of control subjects [68, 741. In summary,
observations in uninephrectomized subjects and kidney recipi-
ents indicate that glomerular hyperfiltration in subjects with a
single kidney is the result of a compensatory increased renal
plasma flow.
In patients with insulin-dependent diabetes mellitus a supra-
normal GFR can be found [751. In these patients the effects of
infusion of a low-dose of dopamine on GFR and ERPF did not
differ from the effects of a low-dose dopamine on GFR and
ERPF of control subjects [76—78]. These observations are in
accord with the assumption that glomerular hyperfiltration of
patients with insulin-dependent diabetes mellitus ensues as the
result of an increase in ,1P rather than of a rise in QA.
Amino acids
Several investigators have demonstrated that short-term ad-
ministration of amino acids (or a meat meal) induces propor-
tional increments in GFR and ERPF of healthy individuals,
resulting in an unchanged FF. By which mechanisms these
stimuli affect GFR is not exactly known but changes in tubulo-
glomerular feedback, glucagon, some unknown (liver-derived?)
metabolic substance, prostaglandins and endothelium-derived
relaxing factor (NO) are thought to be involved. In the rat
infusion of amino acids results in parallel increases of the GFR
and ERPF due to rises in P and QA. whereas Kf doesn't
change [79]. In dogs administration of amino acids also causes
parallel rises in GFR and ERPF [80]. This indicates that AP
and/or K must have increased during amino acid infusion, since
GFR is hardly flow-dependent in dogs. Chan et al [81] have
concluded, using a mathematical model, that the protein-in-
duced rise in GFR in man is also based on rises in P and QA.
From these observations may be inferred that the administra-
tion of amino acids or a meat meal affects renal hemodynamics
by dilation of the afferent arteriole, with a subsequent rise in .P
and QA. The observation of Manno et al [82] that in kidney
donors the administration of a meat meal induces a rise in
microalbuminuria, is in accord with the assumed amino acid (or
meat meal)-induced preglomerular vasodilation.
Interestingly, the effect of protein loading on GFR is depen-
dent on the kind of protein. It has been demonstrated that
especially ingestion of red meat results in an increase in GFR.
Soy-protein has no or only moderate effects [83—86]. Similarly,
branched chain amino acids have no effect, whereas the gluco-
neogenic amino acids seem to be responsible for the rise in GFR
after the administration of an amino acid mixture [87, 88].
As reviewed elsewhere in more detail, the majority of the
published studies to date have reported that the percent amino
acid/meat meal-induced changes in GFR is similar in patients
with renal function impairment and healthy individuals [89—91].
Likewise, no correlation could be found between the percent
amino acid/meat meal-induced changes in GFR and baseline
GFR. Therefore, it is concluded that the administration of a
meat meal or amino acids cannot be used to predict the
presence or absence of glomerular hyperfiltration in patients
with chronic renal failure.
In living-related kidney donors the observed percent amino
acid-induced rises in GFR and ERPF were similar before,
short-term after, and long-term after uninephrectomy [68, 73].
In a number of other studies the protein loading-induced rise in
GFR was similar in control and uninephrectomized subjects
[92—97], although in two studies an impaired response after a
meat meal was found in uninephrectomized individuals [98, 99].
Data in transplant recipients are less consistent. Eisenhauer et
al reported a blunted response to amino acids in transplanted
patients [100]. In another study, the amino acid-induced rise in
azathioprine-prednisolone-treated kidney recipients was identi-
cal to that of their kidney donors before and after kidney
donation [68]. Likewise, Cairns, Raval and Neild found a
significant increase in GFR after amino acids in transplanted
patients who were treated with azathioprine and prednisolone,
whereas no rise in GFR was observed in cyclosporine-treated
individuals [loll. Homan van der Heide et al found that the
amino acid response of the GFR in cyclosporine-treated kidney
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recipients was higher when they were also treated with fish oil
[74]. The latter two studies suggest that cyclosporine impairs
afferent arteriolar responsiveness. Taken together, the majority
of the studies indicate that the response to amino acid infusion
or protein loading is similar in patients with a single kidney and
control subjects. Thus, it may be inferred that the compen-
satory rise in GFR, which can be observed in subjects with
a single kidney, is not based on predominantly afferent vaso-
dilation.
In well-controlled diabetic patients the amino acid-induced
rise in GFR was similar to that of control subjects [102].
Another study reported in a group of insulin-dependent diabet-
ics with supranormal GFR, that the amino acid-induced in-
crease in GFR declined with increasing baseline GFR, whereas
no such relationship existed in healthy individuals [77]. From
this observation it was deducted that glomerular hyperfiltration
of insulin-dependent diabetic patients was based on predomi-
nantly afferent vasodilation. In this group of patients baseline
GFR appeared to be related to serum HbAI levels, and the
amino acid-induced rise in GFR tended to decline with increas-
ing serum HbAI [77]. Bosch et al also demonstrated that the
GFR of type 1 diabetic patients with poor metabolic control did
not rise after a meat meal [103]. From these observations, it
may be deducted that poor metabolic control induces predom-
inantly afferent vasodilation in insulin-dependent diabetic pa-
tients, resulting in glomerular hyperfiltration based on a rise in
iP and QA.
Combined infusion of dopamine and amino acids
As outlined above, dopamine affects renal hemodynamics via
mechanisms other than amino acids or a meat meal. That this
indeed holds true can be deduced from the observations that
combined infusion of dopamine and amino acids results in
additive effects on GFR in healthy individuals, subjects with
renal failure, individuals with a single kidney, and patients with
insulin-dependent diabetes mellitus [68, 73, 77, 104].
Cyclosporine
Cyclosporine (CsA) nephrotoxicity may occur as an acute
decrease in GFR that is rapidly reversible, or as a chronic form
of renal injury which affects most patients treated for more than
one year [105, 106]. The absence of tubular cell necrosis in most
patients with CsA-induced acute renal failure does not support
the assumption that CsA is a tubular toxin, as was initially
proposed [107, 108]. In rats, intravenous administration of CsA
enhances afferent arteriolar resistance, which results in a par-
allel decline in renal perfusion rate and GFR, and is of similar
magnitude as observed in humans [109].
Recently, Perico et al [110] investigated the role of throm-
boxane A2 and of the sulfidopeptide leukotrienes C4 (LTC4)
and D4 (LTD4) in CsA-induced acute renal failure. Pretreat-
ment with the thromboxane A2 receptor antagonist GR 32,191
or the LTC4/LTD4 receptor antagonist L-649,923 partially
prevented the fall in renal plasma flow and GFR induced by one
bolus intravenously administered CsA. The combined infusion
of these two receptor antagonists completely abrogated the
acute decline in renal function that occurred after CsA admin-
istration.
Daily administration of fish oil, containing eicosapentenoic
(= C20:5omega-3) and docosahexenoic (=C22:6 omega-3) fatty
acids, limits thromboxane A2 production in humans [111].
Moreover, long-term administration of fish oil leads to a de-
crease from baseline values in the generation of LTB4 in
Ca-inophore-stimulated neutrophils, as well as to a moderate
production of LTB5 [112, 113]. Interestingly, Homan van der
Heide et al [114] demonstrated in stable, CsA-treated kidney
recipients that compared to corn oil, daily supplementation of
six grams fish oil for three months led to a significantly lower
blood pressure, a significantly higher GFR and ERPF, and a
significant decline in total vascular resistance. The same au-
thors reported in a consecutive, initially placebo-controlled,
double-blind randomized trial in 66 renal graft recipients that
fish oil supplementation during the first postoperative year was
associated with a lower systemic blood pressure, a higher GFR
and ERPF, and significantly less acute rejection episodes [115].
Dietary supplements with omega-3 fatty acids lead to incorpo-
ration of these polyunsaturated fatty acids in phosphoglycerides
of tissue membranes including those of macrophages. This
results in a reduced availability of arachidonic acid and, conse-
quently, in a diminished production of inonoic and dienoic
prostaglandin metabolites. Moreover, moderate amounts of
trienoic prostaglandins will be formed, which possess a differ-
ent spectrum of biological activities. Thus, thromboxane A3 is
a much weaker vasoconstrictor and platelet pro-aggretory sub-
stance than thromboxane A2 [116], and LTB5 a less potent
neutrophiic aggregatory and chemotactic agent than LTB4
[112].
In conclusion, glomerular function can be influenced by
interfering with the tubuloglomerular feedback, and by influ-
encing the balance between the renal vasodilatory and vasocon-
strictive regulatory mechanisms. Future studies will focus on
new agents like specific prostaglandin, angiotensin II, throm-
boxane A2, leukotrienes and nitrix oxide agonists and/or antag-
onists. With these new agents our understanding of glomerular
function, and our therapeutic arsenal, possibly will gain.
Reprint requests to Pieter M. ter Wee, M.D., Department of Medi-
cine, Free University Hospital, P.O. Box 7057, 1007 MB Amsterdam,
The Netherlands.
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